Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Recruiting
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
08/12/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +346 locations
Conditions: Breast Cancer, NOS, CNS Primary Tumor, NOS, Cervical Cancer, NOS, Colorectal Cancer, NOS, Leukemia, NOS, Lymphoma, NOS, Miscellaneous Neoplasm, NOS, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS, Testicular Nonseminomatous Germ Cell Tumor, NOS, Thyroid Cancer, NOS, Melanoma, Bone Cancer, NOS
Register for Updates
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
NCT07109427
Recruiting
- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines. * Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices. * The goal is to reduce late-st... Read More
Gender:
MALE
Ages:
Between 40 years and 75 years
Trial Updated:
08/12/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer, Cancer of the Prostate
Register for Updates
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872
Recruiting
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emerson Clinical Research Institute, Washington, District of Columbia +5 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425
Recruiting
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Investigational Site, Fountain Valley, California +31 locations
Conditions: Atopic Dermatitis
Register for Updates
VIZ ACCESS HCM - Multi-Site Registry
NCT07103057
Recruiting
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Emory University, Atlanta, Georgia +2 locations
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
NCT07100782
Recruiting
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Gender:
FEMALE
Ages:
Between 21 years and 49 years
Trial Updated:
08/12/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Endometriosis, Pelvic Pain
Register for Updates
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Recruiting
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota +5 locations
Conditions: Heart Failure and Reduced Ejection Fraction, Functional Mitral Regurgitation
Register for Updates
Accelerated rTMS vs. Sham for Stroke Apathy
NCT07113067
Recruiting
Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To ad... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/12/2025
Locations: Medical University of South Carolina Brain Stimulation Lab, Charleston, South Carolina
Conditions: Apathy, Stroke, Stroke Sequelae, Stroke/Brain Attack, Stroke/ Cerebrovascular Accident (Ischemic or Hemorrhagic), Motivation, Abulia
Register for Updates
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
NCT04396808
Recruiting
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan +7 locations
Conditions: Prostate Cancer
Register for Updates
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
NCT07108660
Recruiting
Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model. The objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates ve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska +18 locations
Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Register for Updates
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
NCT07002216
Recruiting
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/12/2025
Locations: University of Miami, Miami, Florida
Conditions: Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Register for Updates
Eggs and Age-related Macular Degeneration (EggsAMD) Study.
NCT07021027
Recruiting
Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this rese... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
08/12/2025
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Intermediate Age-Related Macular Degeneration
Register for Updates